Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy.

Pae CU, Serretti A, Mandelli L, De Ronchi D, Patkar AA, Jun TY, Kim JJ, Lee CU, Lee SJ, Lee C, Paik IH.

Pharmacogenet Genomics. 2007 Jan;17(1):69-75.

PMID:
17264804
2.

Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors.

Arias B, Serretti A, Mandelli L, Gastó C, Catalán R, Ronchi DD, Fañanás L.

Pharmacogenet Genomics. 2009 Feb;19(2):121-8. doi: 10.1097/FPC.0b013e32831ebb4b.

PMID:
19065121
3.

Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder.

Kim JJ, Mandelli L, Pae CU, De Ronchi D, Jun TY, Lee C, Paik IH, Patkar AA, Steffens D, Serretti A, Han C.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):375-9.

PMID:
17964051
4.

Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder.

Pae CU, Serretti A, Mandelli L, Yu HS, Patkar AA, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Kim JJ.

Am J Med Genet B Neuropsychiatr Genet. 2007 Jul 5;144B(5):701-3.

PMID:
17192893
5.

DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients.

Pae CU, Drago A, Kim JJ, Patkar AA, Jun TY, Lee C, Mandelli L, De Ronchi D, Paik IH, Serretti A.

Neurosci Lett. 2008 Aug 1;440(2):150-4. doi: 10.1016/j.neulet.2008.05.069. Erratum in: Neurosci Lett. 2008 Dec 19;448(1):170.

PMID:
18562100
6.

Dysbindin gene (DTNBP1) and schizophrenia in Korean population.

Pae CU, Mandelli L, De Ronchi D, Kim JJ, Jun TY, Patkar AA, Serretti A.

Eur Arch Psychiatry Clin Neurosci. 2009 Apr;259(3):137-42. doi: 10.1007/s00406-008-0830-y.

PMID:
19252939
7.

Heat-shock protein-70 genes and response to antidepressants in major depression.

Pae CU, Mandelli L, Serretti A, Patkar AA, Kim JJ, Lee CU, Lee SJ, Lee C, De Ronchi D, Paik IH.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1006-11.

PMID:
17428599
8.

Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response.

Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ, Hou SJ, Yen FC.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):637-41. doi: 10.1016/j.pnpbp.2009.02.020.

PMID:
19272410
9.

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.

Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF.

Arch Gen Psychiatry. 2004 Nov;61(11):1163-9.

PMID:
15520364
10.

No influence of DTNBP1 polymorphisms on the response to aripiprazole.

Pae CU, Chiesa A, Mandelli L, Serretti A.

Neuropsychobiology. 2010;62(4):245-9. doi: 10.1159/000320863.

PMID:
20829635
11.

Baseline severity of depression predicts antidepressant drug response relative to escitalopram.

Kilts CD, Wade AG, Andersen HF, Schlaepfer TE.

Expert Opin Pharmacother. 2009 Apr;10(6):927-36. doi: 10.1517/14656560902849258 .

PMID:
19317630
12.

5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients.

Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serretti A.

Psychiatry Res. 2009 May 15;167(1-2):97-105. doi: 10.1016/j.psychres.2007.12.012.

PMID:
19361869
13.

The dysbindin gene in major depression: an association study.

Zill P, Baghai TC, Engel R, Zwanzger P, Schüle C, Eser D, Behrens S, Rupprecht R, Möller HJ, Ackenheil M, Bondy B.

Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):55-8.

PMID:
15274041
14.

The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.

Wakeno M, Kato M, Okugawa G, Fukuda T, Hosoi Y, Takekita Y, Yamashita M, Nonen S, Azuma J, Kinoshita T.

J Clin Psychopharmacol. 2008 Oct;28(5):518-24. doi: 10.1097/JCP.0b013e31818455fc.

PMID:
18794646
15.

Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran.

Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, Inoue K, Suzuki T, Itoh K, Ozaki N.

Hum Psychopharmacol. 2008 Mar;23(2):121-8.

PMID:
18023073
16.

Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response.

Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ.

Pharmacogenet Genomics. 2008 Oct;18(10):869-75. doi: 10.1097/FPC.0b013e328308bbc0.

PMID:
18794724
17.

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.

Clin Drug Investig. 2007;27(7):481-92.

PMID:
17563128
18.

Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.

Tsai SJ, Hong CJ, Liou YJ, Chen TJ, Chen ML, Hou SJ, Yen FC, Yu YW.

Psychiatry Res. 2009 Sep 30;169(2):113-7. doi: 10.1016/j.psychres.2008.06.028.

PMID:
19700204
19.

Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.

Clerc G; Milnacipran/Fluvoxamine Study Group..

Int Clin Psychopharmacol. 2001 May;16(3):145-51.

PMID:
11354236

Supplemental Content

Support Center